Guardant Health (GH)
(Delayed Data from NSDQ)
$18.10 USD
+0.76 (4.38%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $18.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
GH 18.10 +0.76(4.38%)
Will GH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GH
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
GH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
Other News for GH
Guardant Health assumed with a Buy at Craig-Hallum
Key Takeaways From Guardant Health Analyst Ratings
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
FDA Advisory Panel review of Guardant Health Shield Blood Test on May 23